Identification of Cuproptosis-Related Subtypes, Establishment of a Prognostic Signature and Characterization of the Tumor Microenvironment in Gastric Cancer
Jiazheng Li,Can Kong,Wei Song,Tao Fu
DOI: https://doi.org/10.2147/IJGM.S404847
IF: 2.145
2023-05-03
International Journal of General Medicine
Abstract:Jiazheng Li, 1, &ast Can Kong, 1, &ast Wei Song, 1, &ast Tao Fu 1, 2 1 Department of Gastrointestinal Surgery, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China; 2 Department of General Surgery, Qingdao Municipal Hospital, Qingdao, People's Republic of China &astThese authors contributed equally to this work Correspondence: Tao Fu, Email Purpose: Cuproptosis is a newly identified form of programmed cell death. We aimed to comprehensively discuss the correlation of cuproptosis with gastric cancer (GC) using bioinformatic methods. Patients and Methods: This study selected GC bulk and single-cell RNA sequencing profiles from public databases. Based on the enrichment pattern of cuproptosis-related gene sets (CRGSs), GC patients were classified into different cuproptosis subtypes. A series of systematic analyses was performed to investigate the correlation of cuproptosis subtype with biological function and immune cell infiltration. In addition, we established a CRGS risk score signature to quantify GC patients' risk level, and analyzed the signature's relationship with clinical features, tumor microenvironment (TME) and treatment responses. Genes used for the construction of the risk score model were also detected in GC tumor and normal tissues by real-time quantitative polymerase chain reaction (RT-qPCR). Results: First, analysis of scRNA-seq data revealed the alterations in CRGS enrichment scores for patients with GC and precancerous diseases. Then, based on large GC patient cohorts, two cuproptosis subtypes with significant differences in survival, biological function and TME were identified. Furthermore, we established a CRGS risk score signature. High-risk patients on the CRGS risk score signature with worse overall survival were characterized by higher immune and stromal contents in the TME, more advanced clinicopathological features, and better sensitivity to a wider range of anti-tumor drugs. Low-risk patients were correlated with higher tumor purity, and demonstrated more favorable clinical outcomes and higher sensitivity to immunotherapy. Conclusion: The current work elucidated that cuproptosis plays an important role in the regulation of TME landscapes in GC. Two cuproptosis subtypes with distinct TME characteristics were identified. In addition, the establishment of a CRGS risk score signature could provide novel insights into accurate prediction and personalized treatment for GC patients. Keywords: gastric cancer, cuproptosis, single-cell RNA sequencing, molecular subtype, prognostic model, tumor microenvironment Gastric cancer (GC) is one of the most common malignancies in the digestive system, with high incidence and mortality rates. According to recent statistics, GC was ranked as the fourth leading cause of cancer-related death worldwide, with over 1,000,000 new cases and 700,000 deaths occurring in 2020. 1 Although steady progress has been made in comprehensive management for cancer patients, the prognosis for GC patients remains dismal. Therefore, there is an urgent need to investigate novel treatment strategies for GC patients. Table 1 List of Primers Resistance to cell death is a capability that normal cells acquire during malignant transformation, and is regarded as one of the hallmarks of cancer. 2 Apoptosis was the first mode of programmed cell death (PCD) or cell suicide to be identified in animals. 3 Since its discovery in 1972, efforts have been made to develop anti-cancer treatment strategies targeting apoptosis. The most well-known achievements are navitoclax 4,5 and venetoclax, 6,7 for the treatment of hematological malignancies. In addition to apoptosis, other PCD modes, including autophagy, ferroptosis, pyroptosis and necroptosis, were identified successively, highlighting the potential for non-apoptotic PCD forms to become novel anti-cancer targets. 8 An article published in Science in 2022 presented the discovery of a novel non-apoptotic PCD mode induced by abberant intracellular copper accumulation, named "cuproptosis". 9 Mechanistically, FDX1 is identified as the key initiator of cuproptosis, which promotes the reduction of copper ion from Cu 2+ to the more toxic Cu + . The aberrant Cu + overload triggers two mitochondrial proteotoxic stress pathways: the oligomerization of lipoylated proteins and the destabilization of Fe-S cluster proteins. In addition to the copper overload, it is worth noting that mitochondrial respiration also plays a non-negligible role in cuproptosis, and the cell death could be attenuated by electr -Abstract Truncated-
medicine, general & internal